Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains

Current Alzheimer Research

Volumn 8, Issue 2, 2011, Pages 197-202

  Provias, J ^a   Jeynes, B ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b BROCK UNIVERSITY   (Canada)

Author keywords

AD lesions; Alzheimer's disease; APOE; Blood brain barrier; Capillaries

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; TAU PROTEIN; VASCULOTROPIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENILE PLAQUE;

EID: 79954518983     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720511795256026     Document Type: Article

References (35)

1. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-113 (2009).
2. Jeynes B, Provias J. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathol 112: 417-427 (2006).
3. Jeynes B, Provias J. Evidence for altered LRP /RAGE in Alzheimer lesion pathogenesis. Curr Alz Res 5: 432-437 (2008).
4. Provias J, Jeynes B. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase. Curr Neurovasc Res 5: 199-205 (2008).
5. Jeynes B, Provias J. Correlations between capillary expressed NOS isoforms presence and AD lesions in Alzheimer and normative brains. Neurosci Lett 463: 244-248 (2009).
6. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev/Neurosci 10: 333-344 (2009).
7. De Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol 3: 505-530 (2008).
8. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72: 1487-1494 (2009).
9. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, et al. Cerebral small vessel disease-induced apolipoprotein E leakage is asscociated with Alzheimer disease and the accumulation of amyloid β-protein in perivascular astrocytes. J Neuropathol Exp Neurol 67: 842-856 (2008).
10. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303 (2009).
11. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65: 650-657 (2009).
12. Bu G, Cam J, Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086: 35-53 (2006).
13. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112: 405-415 (2006).
14. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoeE promotes the proteolytic degradation of Aβ. Neuron 58: 681-693 (2008).
15. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-β, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 67: 261-270 (2008).
16. Mateo I, Liorca J, Infanta J, Rodríguez-Rodríguez E, Fernández-Viadero C, Peña N, et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 116: 56-58 (2007).
17. Yuan Q, Zuo X, Jia J. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han. Neurosci Lett 457: 133-136 (2009).
18. Sohn YK, Ganju NG, Bloch KD, Wands JR, de la Monte SM. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci 162: 133-151 (1999).
19. Aliyev A, Seyidova D, Rzayev N, Obrenovich ME, Lamb BT, Chen SG, et al. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res 26: 547-553 (2004).
20. Togo T, Katsuse O, Iseki E. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol Res 26: 563-566 (2004).
21. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Progr Neurobiol 76: 126-152 (2005).
22. Prezedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydtopyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci 93: 4565-4571 (1996).
23. Krizanac-Bengez L, Kapural M, Parkinson F, Cucullo L, Hossain M, Mayberg MR. Effects of transient loss of shear stress on bloodbrain barrier endothelium: role of nitric oxide and Il-6. Brain Res 977: 239-246 (2003).
24. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259 (1991).
25. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
26. Pluta R. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 28: 665-671 (2006).
27. Hirsch-Reinshagen V, Burgess BL, Wellington C L. Why lipids are important for Alzheimer disease. Mol Cell Biochem 326: 121-129 (2009).
28. Fan J, Donkin J, Wellington C. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors 35: 239-248 (2009).
29. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118: 4002-4013 (2008).
30. Carter DB. The interaction of amyloid-beta with ApoE. Subcell Biochem 38: 255-272 (2005).
31. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10: 719-726 (2004).
32. Bruinsma I B, Wilhelmus MM, Kox M, Veerhuis R, de Waal RM, Verbeek MM. Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta (1-40)-mediated cell death. Brain Res 2010; In Press.
33. Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, Delong C, et al. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci 29: 3603-3612 (2009).
34. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197 (2007).
35. Singh S, Thakur MK. Age-dependent expression of apolipoprotein E in mouse cerebral cortex. J Mol Neurosci 9412-9413 (2010).